No Picture
News

New tool developed to study ‘undruggable’ proteins

Researchers at Harvard have designed new, highly selective tools that can add or remove sugars from a protein with no off-target effects, to examine exactly what the sugars are doing and engineer them into new treatments for “undruggable” proteins. Click here to view original post… […]

No Picture
News

Another Corbus program hits the skids after late-stage flop, plummeting the small biotech’s shares

Corbus Pharmaceuticals’ plans to position lenabasum as a pipeline-in-a-product aren’t going so well. After shelving a program in scleroderma, the Norwood, MA-based biotech has revealed that its lead candidate failed both the primary and secondary endpoints in another Phase III trial. Lenabasum failed to show a statistically significant difference in… Click here to view original post… […]

No Picture
News

Lyndra Therapeutics Completes $60.5 Million Series C Financing

WATERTOWN, Mass.–(BUSINESS WIRE)–Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C financing. The proceeds of the round, led by new investor, AIG Investments, an affiliate of American… Click here to view original post… […]